The Aurora kinase inhibitors in cancer research and therapy

Adams RR, Wheatley SP, Gouldsworthy AM, Kandels-Lewis SE, Carmena M, Smythe C, Gerloff DL, Earnshaw WC (2000) INCENP binds the Aurora-related kinase AIRK2 and is required to target it to chromosomes, the central spindle and cleavage furrow. Curr Biol 10(17):1075–1078PubMedCrossRef

Adams ND, Adams JL, Burgess JL, Chaudhari AM, Copeland RA, Donatelli CA, Drewry DH, Fisher KE, Hamajima T, Hardwicke MA, Huffman WF, Koretke-Brown KK, Lai ZV, McDonald OB, Nakamura H, Newlander KA, Oleykowski CA, Parrish CA, Patrick DR, Plant R, Sarpong MA, Sasaki K, Schmidt SJ, Silva DJ, Sutton D, Tang J, Thompson CS, Tummino PJ, Wang JC, Xiang H, Yang J, Dhanak D (2010) Discovery of GSK1070916, a potent and selective inhibitor of Aurora B/C kinase. J Med Chem 53(10):3973–4001. doi:10.1021/jm901870q PubMedCrossRef

Aihara A, Tanaka S, Yasen M, Matsumura S, Mitsunori Y, Murakata A, Noguchi N, Kudo A, Nakamura N, Ito K, Arii S (2010) The selective Aurora B kinase inhibitor AZD1152 as a novel treatment for hepatocellular carcinoma. J Hepatol 52(1):63–71. doi:10.1016/j.jhep.2009.10.013 PubMedCrossRef

Akahane D, Tauchi T, Okabe S, Nunoda K, Ohyashiki K (2008) Activity of a novel Aurora kinase inhibitor against the T315I mutant form of BCR-ABL: in vitro and in vivo studies. Cancer Sci 99(6):1251–1257. doi:10.1111/j.1349-7006.2008.00810.x PubMedCrossRef

Amin M, Minton SE, LoRusso PM, Krishnamurthi SS, Pickett CA, Lunceford J, Hille D, Mauro D, Stein MN, Wang-Gillam A, Trull L, Lockhart AC (2015) A phase I study of MK-5108, an oral aurora a kinase inhibitor, administered both as monotherapy and in combination with docetaxel, in patients with advanced or refractory solid tumors. Invest New Drugs 34(1):84–95. doi:10.1007/s10637-015-0306-7 PubMedCrossRef

Anderson K, Lai Z, McDonald OB, Stuart JD, Nartey EN, Hardwicke MA, Newlander K, Dhanak D, Adams J, Patrick D, Copeland RA, Tummino PJ, Yang J (2009) Biochemical characterization of GSK1070916, a potent and selective inhibitor of Aurora B and Aurora C kinases with an extremely long residence time1. Biochem J 420(2):259–265. doi:10.1042/BJ20090121 PubMedCrossRef

Ando R, Ikegami H, Sakiyama M, Ooike S, Hayashi M, Fujino Y, Abe D, Nakamura H, Mishina T, Kato H, Iwase Y, Tomozane H, Morioka M (2010) 3-Cyano-6-(5-methyl-3-pyrazoloamino)pyridines: selective Aurora A kinase inhibitors. Bioorg Med Chem Lett 20(15):4709–4711. doi:10.1016/j.bmcl.2010.04.119 PubMedCrossRef

Andrews PD, Ovechkina Y, Morrice N, Wagenbach M, Duncan K, Wordeman L, Swedlow JR (2004) Aurora B regulates MCAK at the mitotic centromere. Dev Cell 6(2):253–268PubMedCrossRef

Arbitrario JP, Belmont BJ, Evanchik MJ, Flanagan WM, Fucini RV, Hansen SK, Harris SO, Hashash A, Hoch U, Hogan JN, Howlett AR, Jacobs JW, Lam JW, Ritchie SC, Romanowski MJ, Silverman JA, Stockett DE, Teague JN, Zimmerman KM, Taverna P (2010) SNS-314, a pan-Aurora kinase inhibitor, shows potent anti-tumor activity and dosing flexibility in vivo. Cancer Chemother Pharmacol 65(4):707–717. doi:10.1007/s00280-009-1076-8 PubMedCrossRef

Arlot-Bonnemains Y, Baldini E, Martin B, Delcros JG, Toller M, Curcio F, Ambesi-Impiombato FS, D’Armiento M, Ulisse S (2008) Effects of the Aurora kinase inhibitor VX-680 on anaplastic thyroid cancer-derived cell lines. Endocr Relat Cancer 15(2):559–568. doi:10.1677/ERC-08-0021 PubMedCrossRef

Baldini E, Sorrenti S, D’Armiento E, Guaitoli E, Morrone S, D’Andrea V, Gnessi L, Moretti C, Antonelli A, Catania A, De Antoni E, Ulisse S (2012) Effects of the Aurora kinases pan-inhibitor SNS-314 mesylate on anaplastic thyroid cancer derived cell lines. Clin Ter 163(5):e307–e313PubMed

Barr PM, Li H, Spier C, Mahadevan D, LeBlanc M, Ul Haq M, Huber BD, Flowers CR, Wagner-Johnston ND, Horwitz SM, Fisher RI, Cheson BD, Smith SM, Kahl BS, Bartlett NL, Friedberg JW (2015) Phase II intergroup trial of alisertib in relapsed and refractory peripheral T-cell lymphoma and transformed mycosis fungoides: SWOG 1108. J Clin Oncol 33(21):2399–2404. doi:10.1200/JCO.2014.60.6327 PubMedPubMedCentralCrossRef

Bavetsias V, Large JM, Sun C, Bouloc N, Kosmopoulou M, Matteucci M, Wilsher NE, Martins V, Reynisson J, Atrash B, Faisal A, Urban F, Valenti M, de Haven BA, Box G, Raynaud FI, Workman P, Eccles SA, Bayliss R, Blagg J, Linardopoulos S, McDonald E (2010) Imidazo[4,5-b]pyridine derivatives as inhibitors of Aurora kinases: lead optimization studies toward the identification of an orally bioavailable preclinical development candidate. J Med Chem 53(14):5213–5228. doi:10.1021/jm100262j PubMedCrossRef

Bergqvist J, Elmberger G, Ohd J, Linderholm B, Bjohle J, Hellborg H, Nordgren H, Borg AL, Skoog L, Bergh J (2006) Activated ERK1/2 and phosphorylated oestrogen receptor alpha are associated with improved breast cancer survival in women treated with tamoxifen. Eur J Cancer 42(8):1104–1112. doi:10.1016/j.ejca.2006.01.028 PubMedCrossRef

Borges KS, Castro-Gamero AM, Moreno DA, da Silva SV, Brassesco MS, de Paula Queiroz RG, de Oliveira HF, Carlotti CG Jr, Scrideli CA, Tone LG (2012) Inhibition of Aurora kinases enhances chemosensitivity to temozolomide and causes radiosensitization in glioblastoma cells. J Cancer Res Clin Oncol 138(3):405–414. doi:10.1007/s00432-011-1111-0 PubMedCrossRef

Borges KS, Moreno DA, Martinelli CE Jr, Antonini SR, de Castro M, Tucci S Jr, Neder L, Ramalho LN, Seidinger AL, Cardinalli I, Mastellaro MJ, Yunes JA, Brandalise SR, Tone LG, Scrideli CA (2013) Spindle assembly checkpoint gene expression in childhood adrenocortical tumors (ACT): overexpression of Aurora kinases A and B is associated with a poor prognosis. Pediatr Blood Cancer 60(11):1809–1816. doi:10.1002/pbc.24653 PubMedCrossRef

Boss DS, Witteveen PO, van der Sar J, Lolkema MP, Voest EE, Stockman PK, Ataman O, Wilson D, Das S, Schellens JH (2011) Clinical evaluation of AZD1152, an i.v. inhibitor of Aurora B kinase, in patients with solid malignant tumors. Ann Oncol 22(2):431–437. doi:10.1093/annonc/mdq344 PubMedCrossRef

Carducci MA, Shaheen MF, Paller CJ, Bauman JE, Azad NS, Shubhakar P, Tang R, Stroh M, Friberg GR, Verschraegen CF (2012) J Clin Oncol 30 (suppl; abstr 3009). http://meetinglibrary.asco.org/content/92852-114

Carmena M, Earnshaw WC (2003) The cellular geography of aurora kinases. Nat Rev Mol Cell Biol 4(11):842–854PubMedCrossRef

Carpinelli P, Moll J (2008) Aurora kinases and their inhibitors: more than one target and one drug. Adv Exp Med Biol 610:54–73. doi:10.1007/978-0-387-73898-7_5 PubMedCrossRef

Cervantes A, Elez E, Roda D, Ecsedy J, Macarulla T, Venkatakrishnan K, Roselló S, Andreu J, Jung J, Sanchis-Garcia JM, Piera A, Blasco I, Maños L, Pérez-Fidalgo JA, Fingert H, Baselga J, Tabernero J (2012) Phase I pharmacokinetic/pharmacodynamics study of MLN8237, an investigational, oral, selective aurora a kinase inhibitor, in patients with advanced solid tumors. Clin Cancer Res 18(17):4764–4774. doi:10.1158/1078-0432.CCR-12-0571 PubMedCrossRef

Chakravarty A, Shinde V, Tabernero J, Cervantes A, Cohen RB, Dees EC, Burris H, Infante JR, Macarulla T, Elez E, Andreu J, Rodriguez-Braun E, Rosello S, von Mehren M, Meropol NJ, Langer CJ, ONeil B, Bowman D, Zhang M, Danaee H, Faron-Yowe L, Gray G, Liu H, Pappas J, Silverman L, Simpson C, Stringer B, Tirrell S, Veiby OP, Venkatakrishnan K, Galvin K, Manfredi M, Ecsedy JA (2011) Phase I assessment of new mechanism-based pharmacodynamic biomarkers for MLN8054, a small-molecule inhibitor of Aurora A kinase. Cancer Res 71(3):675–685. doi:10.1158/0008-5472.CAN-10-1030 PubMedCrossRef

Chinn DC, Holland WS, Mack PC (2014) Anticancer activity of the Aurora A kinase inhibitor MK-5108 in non-small-cell lung cancer (NSCLC) in vitro as monotherapy and in combination with chemotherapies. J Cancer Res Clin Oncol 140(7):1137–1149. doi:10.1007/s00432-014-1675-6 PubMedPubMedCentralCrossRef

Choi JE, Woo SM, Min KJ, Kang SH, Lee SJ, Kwon TK (2015) Combined treatment with ABT-737 and VX-680 induces apoptosis in Bcl-2- and c-FLIP-overexpressing breast carcinoma cells. Oncol Rep. 33(3):1395–401. doi:10.3892/or.2015.3728 PubMed

Cicenas J (2007) The potential role of EGFR/ErbB2 heterodimer in breast cancer. Expert Opin Ther Patents 17(6):607–616. doi:10.1517/13543776.17.6.607 CrossRef

Cicenas J (2008) The potential role of Akt phosphorylation in human cancers. Int J Bio Markers 23(1):1–9

Cicenas J (2015) JNK inhibitors: is there a future? MAP Kinase 4(1):32–38. doi:10.4081/mk.2015.5700 CrossRef

Cicenas J, Valius M (2011) The CDK inhibitors in cancer research and therapy. J Cancer Res Clin Oncol 137(10):1409–1418. doi:10.1007/s00432-011-1039-4 PubMedCrossRef

Cicenas J, Urban P, Vuaroqueaux V, Labuhn M, Küng W, Wight E, Mayhew M, Eppenberger U, Eppenberger-Castori S (2005) Increased level of phosphorylated akt measured by chemiluminescence-linked immunosorbent assay is a predictor of poor prognosis in primary breast cancer overexpressing ErbB-2. Breast Cancer Res 7(4):R394–R401. doi:10.1186/bcr1015 PubMedPubMedCentralCrossRef

Cicenas J, Urban P, Küng W, Vuaroqueaux V, Labuhn M, Wight E, Eppenberger U, Eppenberger-Castori S (2006) Phosphorylation of tyrosine 1248-ERBB2 measured by chemiluminescence-linked immunoassay is an independent predictor of poor prognosis in primary breast cancer patients. Eur J Cancer 42(5):636–645. doi:10.1016/j.ejca.2005.11.012 PubMedCrossRef

Cicenas J, Küng W, Eppenberger U, Eppenberger-Castori S (2010) Increased level of phosphorylated ShcA measured by chemiluminescence- linked immunoassay is a predictor of good prognosis in primary breast cancer expressing low levels of estrogen receptor. Cancers 2(1):153–164. doi:10.3390/cancers2010153 PubMedPubMedCentralCrossRef

Cicenas J, Kalyan K, Sorokinas A, Jatulyte A, Valiunas D, Kaupinis A, Valius M (2014) Highlights of the latest advances in research on CDK inhibitors. Cancers (Basel) 6(4):2224–2242. doi:10.3390/cancers6042224 CrossRef

Cicenas J, Kalyan K, Sorokinas A, Stankunas E, Levy J, Meskinyte I, Stankevicius V, Kaupinis A, Valius M (2015) Roscovitine in cancer and other diseases. Ann Transl Med 3(10):135. doi:10.3978/j.issn.2305-5839.2015.03.6 PubMedPubMedCentral

Clarke RB (2003) p27KIP1 phosphorylation by PKB/Akt leads to poor breast cancer prognosis. Breast Cancer Res 5(3):162–163. doi:10.1186/bcr596 PubMedPubMedCentralCrossRef

Collins GP, Eyre TA, Linton KM, Radford J, Vallance GD, Soilleux E, Hatton C (2015) A phase II trial of AZD1152 in relapsed/refractory diffuse large B-cell lymphoma. Br J Haematol 170(6):886–890. doi:10.1111/bjh.13333 PubMedCrossRef

Dai Y, Chen S, Venditti CA, Pei XY, Nguyen TK, Dent P, Grant S (2008) Vorinostat synergistically potentiates MK-0457 lethality in chronic myelogenous leukemia cells sensitive and resistant to imatinib mesylate. Blood 112(3):793–804. doi:10.1182/blood-2007-10-116376 PubMedPubMedCentralCrossRef

Dar AA, Belkhiri A, Ecsedy J, Zaika A, El-Rifai W (2008) Aurora kinase A inhibition leads to p73-dependent apoptosis in p53-deficient cancer cells. Cancer Res 68(21):8998–9004. doi:10.1158/0008-5472.CAN-08-2658 PubMedPubMedCentralCrossRef

Dees EC, Infante JR, Cohen RB, O’Neil BH, Jones S, von Mehren M, Danaee H, Lee Y, Ecsedy J, Manfredi M, Galvin K, Stringer B, Liu H, Eton O, Fingert H, Burris H (2011) Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumors. Cancer Chemother Pharmacol 67(4):945–954. doi:10.1007/s00280-010-1377-y PubMedCrossRef

Dees EC, Cohen RB, von Mehren M, Stinchcombe TE, Liu H, Venkatakrishnan K, Manfredi M, Fingert H, Burris HA 3rd, Infante JR (2012) Phase I study of aurora A kinase inhibitor MLN8237 in advanced solid tumors: safety, pharmacokinetics, pharmacodynamics, and bioavailability of two oral formulations. Clin Cancer Res 18(17):4775–4784. doi:10.1158/1078-0432 PubMedCrossRef

Dennis M, Davies M, Oliver S, D’Souza R, Pike L, Stockman P (2012) Phase I study of the Aurora B kinase inhibitor barasertib (AZD1152) to assess the pharmacokinetics, metabolism and excretion in patients with acute myeloid leukemia. Cancer Chemother Pharmacol 70(3):461–469. doi:10.1007/s00280-012-1939-2 PubMedPubMedCentralCrossRef

Derenzini M, Montanaro L, Vici M, Barbieri S, Ceccarelli C, Santini D, TaVurelli M, Martinelli GN, Treré D (2007) Relationship between the RB1 mRNA level and the expression of phosphorylated RB protein in human breast cancers: their relevance in cell proliferation activity and patient clinical outcome. Histol Histopathol 22(5):505–513PubMed

DiGiovanna MP, Stern DF, Edgerton SM, Whalen SG, Moore D 2nd, Thor AD (2005) Relationship of epidermal growth factor receptor expression to ErbB-2 signaling activity and prognosis in breast cancer patients. J Clin Oncol 23(6):1152–1160. doi:10.1200/JCO.2005.09.055 PubMedCrossRef

Druker BJ (2002) STI571 (Gleevec) as a paradigm for cancer therapy. Trends Mol Med 8(4 Suppl):S14-8PubMed

Evans RP, Naber C, Steffler T, Checkland T, Maxwell CA, Keats JJ, Belch AR, Pilarski LM, Lai R, Reiman T (2008) The selective Aurora B kinase inhibitor AZD1152 is a potential new treatment for multiple myeloma. Br J Haematol 140(3):295–302PubMedCrossRef

Faisal A, Vaughan L, Bavetsias V, Sun C, Atrash B, Avery S, Jamin Y, Robinson SP, Workman P, Blagg J, Raynaud FI, Eccles SA, Chesler L, Linardopoulos S (2011) The aurora kinase inhibitor CCT137690 downregulates MYCN and sensitizes MYCN-amplified neuroblastoma in vivo. Mol Cancer Ther 10(11):2115–2123. doi:10.1158/1535-7163.MCT-11-0333 PubMedPubMedCentralCrossRef

Falchook G, Kurzrock R, Gouw L, Hong D, McGregor KA, Zhou X, Shi H, Fingert H, Sharma S (2014) Investigational Aurora A kinase inhibitor alisertib (MLN8237) as an enteric-coated tablet formulation in non-hematologic malignancies: phase 1 dose-escalation study. Invest New Drugs 32(6):1181–1187. doi:10.1007/s10637-014-0121-6 PubMedPubMedCentralCrossRef

Ferrari S, Marin O, Pagano MA, Meggio F, Hess D, El-Shemerly M, Krystyniak A, Pinna LA (2005) Aurora-A site specificity: a study with synthetic peptide substrates. Biochem J 390(Pt 1):293–302PubMedPubMedCentralCrossRef

Fiskus W, Wang Y, Joshi R, Rao R, Yang Y, Chen J, Kolhe R, Balusu R, Eaton K, Lee P, Ustun C, Jillella A, Buser CA, Peiper S, Bhalla K (2008) Cotreatment with vorinostat enhances activity of MK-0457 (VX-680) against acute and chronic myelogenous leukemia cells. Clin Cancer Res 14(19):6106–6115. doi:10.1158/1078-0432.CCR-08-0721 PubMedPubMedCentralCrossRef

Fu S, Li Y, Huang J, Liu T, Hong Z, Chen A, Bast RC, Kavanagh JJ, Gershenson DM, Sood AK, Hu W (2012) Aurora kinase inhibitor VE 465 synergistically enhances cytotoxicity of carboplatin in ovarian cancer cells through induction of apoptosis and downregulation of histone 3. Cancer Biol Ther 13(11):1034–1041. doi:10.4161/cbt.21045 PubMedPubMedCentralCrossRef

Gabillard JC, Ulisse S, Baldini E, Sorrenti S, Cremet JY, Coccaro C, Prigent C, D’Armiento M, Arlot-Bonnemains Y (2011) Aurora-C interacts with and phosphorylates the transforming acidic coiled-coil 1 protein. Biochem Biophys Res Commun 408(4):647–653. doi:10.1016/j.bbrc.2011.04.078 PubMedCrossRef

Georgieva I, Koychev D, Wang Y, Holstein J, Hopfenmüller W, Zeitz M, Grabowski P (2010) ZM447439, a novel promising aurora kinase inhibitor, provokes antiproliferative and proapoptotic effects alone and in combination with bio- and chemotherapeutic agents in gastroenteropancreatic neuroendocrine tumor cell lines. Neuroendocrinology 91(2):121–130. doi:10.1159/000258705 PubMedCrossRef

Geuns-Meyer S, Cee VJ, Deak HL, Du B, Hodous BL, Nguyen HN, Olivieri PR, Schenkel LB, Vaida KR, Andrews P, Bak A, Be X, Beltran PJ, Bush TL, Chaves MK, Chung G, Dai Y, Eden P, Hanestad K, Huang L, Lin MH, Tang J, Ziegler B, Radinsky R, Kendall R, Patel VF, Payton M (2015) Discovery of N-(4-(3-(2-aminopyrimidin-4-yl)pyridin-2-yloxy)phenyl)-4-(4-methylthiophen-2-yl)phthalazin-1-amine (AMG 900), a highly selective, orally bioavailable inhibitor of aurora kinases with activity against multidrug-resistant cancer cell lines. J Med Chem 58(13):5189–5207. doi:10.1021/acs.jmedchem.5b00183 PubMedCrossRef

Gharwan H, Groninger H (2015) Kinase inhibitors and monoclonal antibodies in oncology: clinical implications. Nat Rev Clin Oncol. doi:10.1038/nrclinonc.2015.213 PubMed

Giles FJ, Cortes J, Jones D, Bergstrom D, Kantarjian H, Freedman SJ (2007) MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. Blood 109(2):500–502PubMedCrossRef

Giles FJ, Swords RT, Nagler A, Hochhaus A, Ottmann OG, Rizzieri DA, Talpaz M, Clark J, Watson P, Xiao A, Zhao B, Bergstrom D, Le Coutre PD, Freedman SJ, Cortes JE (2013) MK-0457, an Aurora kinase and BCR-ABL inhibitor, is active in patients with BCR-ABL T315I leukemia. Leukemia 27(1):113–117. doi:10.1038/leu.2012.186 PubMedCrossRef

Glover DM, Leibowitz MH, McLean DA, Parry H (1995) Mutations in aurora prevent centrosome separation leading to the formation of monopolar spindles. Cell 81(1):95–105PubMedCrossRef

Goldberg SL, Fenaux P, Craig MD, Gyan E, Lister J, Kassis J, Pigneux A, Schiller GJ, Jung J, Jane Leonard E, Fingert H, Westervelt P (2014) An exploratory phase 2 study of investigational Aurora A kinase inhibitor alisertib (MLN8237) in acute myelogenous leukemia and myelodysplastic syndromes. Leuk Res Rep 3(2):58–61. doi:10.1016/j.lrr.2014.06.003 PubMedPubMedCentral

Görgün G, Calabrese E, Hideshima T, Ecsedy J, Perrone G, Mani M, Ikeda H, Bianchi G, Hu Y, Cirstea D, Santo L, Tai YT, Nahar S, Zheng M, Bandi M, Carrasco RD, Raje N, Munshi N, Richardson P, Anderson KC (2010) A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma. Blood 115(25):5202–5213. doi:10.1182/blood-2009-12-259523 PubMedPubMedCentralCrossRef

Goto H, Yasui Y, Kawajiri A, Nigg EA, Terada Y, Tatsuka M, Nagata K, Inagaki M (2003) Aurora-B regulates the cleavage furrow-specific vimentin phosphorylation in the cytokinetic process. J Biol Chem 278(10):8526–8530PubMedCrossRef

Grundy M, Seedhouse C, Shang S, Richardson J, Russell N, Pallis M (2010) The FLT3 internal tandem duplication mutation is a secondary target of the aurora B kinase inhibitor AZD1152-HQPA in acute myelogenous leukemia cells. Mol Cancer Ther 9(3):661–672. doi:10.1158/1535-7163.MCT-09-1144 PubMedCrossRef

Hardwicke MA, Oleykowski CA, Plant R, Wang J, Liao Q, Moss K, Newlander K, Adams JL, Dhanak D, Yang J, Lai Z, Sutton D, Patrick D (2009) GSK1070916, a potent Aurora B/C kinase inhibitor with broad antitumor activity in tissue culture cells and human tumor xenograft models. Mol Cancer Ther 8(7):1808–1817. doi:10.1158/1535-7163.MCT-09-0041 PubMedCrossRef

Harrington EA, Bebbington D, Moore J, Rasmussen RK, Ajose-Adeogun AO, Nakayama T, Graham JA, Demur C, Hercend T, Diu-Hercend A, Su M, Golec JM, Miller KM (2004) VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat Med 10(3):262–267PubMedCrossRef

Hauf S, Cole RW, LaTerra S, Zimmer C, Schnapp G, Walter R, Heckel A, van Meel J, Rieder CL, Peters JM (2003) The small molecule Hesperadin reveals a role for Aurora B in correcting kinetochore-microtubule attachment and in maintaining the spindle assembly checkpoint. J Cell Biol 161(2):281–294PubMedPubMedCentralCrossRef

Hirota T, Kunitoku N, Sasayama T, Marumoto T, Zhang D, Nitta M, Hatakeyama K, Saya H (2003) Aurora-A and an interacting activator, the LIM protein Ajuba, are required for mitotic commitment in human cells. Cell 114(5):585–598PubMedCrossRef

Honda R, Körner R, Nigg EA (2003) Exploring the functional interactions between Aurora B, INCENP, and survivin in mitosis. Mol Biol Cell 14(8):3325–3341PubMedPubMedCentralCrossRef

Hook KE, Garza SJ, Lira ME, Ching KA, Lee NV, Cao J, Yuan J, Ye J, Ozeck M, Shi ST, Zheng X, Rejto PA, Kan JL, Christensen JG, Pavlicek A (2012) An integrated genomic approach to identify predictive biomarkers of response to the aurora kinase inhibitor PF-03814735. Mol Cancer Ther 11(3):710–719. doi:10.1158/1535-7163 PubMedCrossRef

Horn V, Thélu J, Garcia A, Albigès-Rizo C, Block MR, Viallet J (2007) Functional interaction of Aurora-A and PP2A during mitosis. Mol Biol Cell 18(4):1233–1241PubMedPubMedCentralCrossRef

Huang XF, Luo SK, Xu J, Li J, Xu DR, Wang LH, Yan M, Wang XR, Wan XB, Zheng FM, Zeng YX, Liu Q (2008) Aurora kinase inhibitory VX-680 increases Bax/Bcl-2 ratio and induces apoptosis in Aurora-A-high acute myeloid leukemia. Blood 111(5):2854–2865PubMedCrossRef

Huck JJ, Zhang M, McDonald A, Bowman D, Hoar KM, Stringer B, Ecsedy J, Manfredi MG, Hyer ML (2010) MLN8054, an inhibitor of Aurora A kinase, induces senescence in human tumor cells both in vitro and in vivo. Mol Cancer Res 8(3):373–384. doi:10.1158/1541-7786 PubMedCrossRef

Hutterer A, Berdnik D, Wirtz-Peitz F, Zigman M, Schleiffer A, Knoblich JA (2006) Mitotic activation of the kinase Aurora-A requires its binding partner Bora. Dev Cell 11(2):147–157PubMedCrossRef

Ikeda M, Chiba S, Ohashi K, Mizuno K (2012) Furry protein promotes aurora A-mediated Polo-like kinase 1 activation. J Biol Chem 287(33):27670–27681. doi:10.1074/jbc.M112.378968 PubMedPubMedCentralCrossRef

Jang CY, Coppinger JA, Seki A, Yates JR 3rd, Fang G (2009) Plk1 and Aurora A regulate the depolymerase activity and the cellular localization of Kif2a. J Cell Sci 122(Pt 9):1334–1341. doi:10.1242/jcs.044321 PubMedPubMedCentralCrossRef

Jani JP, Arcari J, Bernardo V, Bhattacharya SK, Briere D, Cohen BD, Coleman K, Christensen JG, Emerson EO, Jakowski A, Hook K, Los G, Moyer JD, Pruimboom-Brees I, Pustilnik L, Rossi AM, Steyn SJ, Su C, Tsaparikos K, Wishka D, Yoon K, Jakubczak JL (2010) PF-03814735, an orally bioavailable small molecule aurora kinase inhibitor for cancer therapy. Mol Cancer Ther 9(4):883–894. doi:10.1158/1535-7163 PubMedCrossRef

Jänne PA, Gray N, Settleman J (2009) Factors underlying sensitivity of cancers to small-molecule kinase inhibitors. Nat Rev Drug Discov 8(9):709–723. doi:10.1038/nrd2871 PubMedCrossRef

Jetton N, Rothberg KG, Hubbard JG, Wise J, Li Y, Ball HL, Ruben L (2009) The cell cycle as a therapeutic target against Trypanosoma brucei: Hesperadin inhibits Aurora kinase-1 and blocks mitotic progression in bloodstream forms. Mol Microbiol 72(2):442–458. doi:10.1111/j.1365-2958.2009.06657.x PubMedPubMedCentralCrossRef

Jeyaprakash AA, Klein UR, Lindner D, Ebert J, Nigg EA, Conti E (2007) Structure of a Survivin–Borealin–INCENP core complex reveals how chromosomal passengers travel together. Cell 131(2):271–285PubMedCrossRef

Kaitna S, Pasierbek P, Jantsch M, Loidl J, Glotzer M (2002) The aurora B kinase AIR-2 regulates kinetochores during mitosis and is required for separation of homologous chromosomes during meiosis. Curr Biol 12(10):798–812PubMedCrossRef

Kanematsu T, Yano S, Uehara H, Bando Y, Sone S (2003) Phosphorylation, but not overexpression, of epidermal growth factor receptor is associated with poor prognosis of non-small cell lung cancer patients. Oncol Res 13(5):289–298PubMed

Kantarjian HM, Sekeres MA, Ribrag V, Rousselot P, Garcia-Manero G, Jabbour EJ, Owen K, Stockman PK, Oliver SD (2013) Phase I study assessing the safety and tolerability of barasertib (AZD1152) with low-dose cytosine arabinoside in elderly patients with AML. Clin Lymphoma Myeloma Leuk 13(5):559–567. doi:10.1016/j.clml.2013.03.019 PubMedPubMedCentralCrossRef

Katayama H, Zhou H, Li Q, Tatsuka M, Sen S (2001) Interaction and feedback regulation between STK15/BTAK/Aurora-A kinase and protein phosphatase 1 through mitotic cell division cycle. J Biol Chem 276(49):46219–46224PubMedCrossRef

Kawajiri A, Yasui Y, Goto H, Tatsuka M, Takahashi M, Nagata K, Inagaki M (2003) Functional significance of the specific sites phosphorylated in desmin at cleavage furrow: Aurora-B may phosphorylate and regulate type III intermediate filaments during cytokinesis coordinatedly with Rho-kinase. Mol Biol Cell 14(4):1489–1500PubMedPubMedCentralCrossRef

Keizer RJ, Zandvliet AS, Beijnen JH, Schellens JH, Huitema AD (2012) Two-stage model-based design of cancer phase I dose escalation trials: evaluation using the phase I program of barasertib (AZD1152). Invest New Drugs 30(4):1519–1530. doi:10.1007/s10637-011-9694-5 PubMedCrossRef

Kelly KR, Ecsedy J, Medina E, Mahalingam D, Padmanabhan S, Nawrocki ST, Giles FJ, Carew JS (2011) The novel Aurora A kinase inhibitor MLN8237 is active in resistant chronic myeloid leukaemia and significantly increases the efficacy of nilotinib. J Cell Mol Med 15(10):2057–2070. doi:10.1111/j.1582-4934.2010.01218.x PubMedPubMedCentralCrossRef

Kelly KR, Shea TC, Goy A, Berdeja JG, Reeder CB, McDonagh KT, Zhou X, Danaee H, Liu H, Ecsedy JA, Niu H, Benaim E, Iyer SP (2014) Phase I study of MLN8237—investigational Aurora A kinase inhibitor—in relapsed/refractory multiple myeloma, non-Hodgkin lymphoma and chronic lymphocytic leukemia. Invest New Drugs 32(3):489–499. doi:10.1007/s10637-013-0050-9 PubMedCrossRef

Kimmins S, Crosio C, Kotaja N, Hirayama J, Monaco L, Höög C, van Duin M, Gossen JA, Sassone-Corsi P (2007) Differential functions of the Aurora-B and Aurora-C kinases in mammalian spermatogenesis. Mol Endocrinol 21(3):726–739PubMedCrossRef

Kufer TA, Silljé HH, Körner R, Gruss OJ, Meraldi P, Nigg EA (2002) Human TPX2 is required for targeting Aurora-A kinase to the spindle. J Cell Biol 158(4):617–623PubMedPubMedCentralCrossRef

Kunitoku N, Sasayama T, Marumoto T, Zhang D, Honda S, Kobayashi O, Hatakeyama K, Ushio Y, Saya H, Hirota T (2003) CENP-A phosphorylation by Aurora-A in prophase is required for enrichment of Aurora-B at inner centromeres and for kinetochore function. Dev Cell 5(6):853–864PubMedCrossRef

Ladygina NG, Latsis RV, Yen T (2005) Effect of the pharmacological agent hesperidin on breast and prostate tumor cultured cells. Biomed Khim 51(2):170–176PubMed

Lee PY, Chen CL, Lin ZZ, Cheng AL, Chen EI, Whang-Peng J, Huang CY (2013) The Aurora kinases inhibitor VE-465 is a novel treatment for glioblastoma multiforme. Oncology 6:326–335. doi:10.1159/000347021 CrossRef

Li JJ, Li SA (2006) Mitotic kinases: the key to duplication, segregation, and cytokinesis errors, chromosomal instability, and oncogenesis. Pharmacol Ther 111(3):974–984PubMedCrossRef

Li Y, Zhang ZF, Chen J, Huang D, Ding Y, Tan MH, Qian CN, Resau JH, Kim H, Teh BT (2010) VX680/MK-0457, a potent and selective Aurora kinase inhibitor, targets both tumor and endothelial cells in clear cell renal cell carcinoma. Am J Transl Res 2(3):296–308PubMedPubMedCentral

Li JP, Yang YX, Liu QL, Pan ST, He ZX, Zhang X, Yang T, Chen XW, Wang D, Qiu JX, Zhou SF (2015) The investigational Aurora kinase A inhibitor alisertib (MLN8237) induces cell cycle G2/M arrest, apoptosis, and autophagy via p38 MAPK and Akt/mTOR signaling pathways in human breast cancer cells. Drug Des Devel Ther 9:1627–1652. doi:10.2147/DDDT.S75378 PubMedPubMedCentral

Lin YG, Immaneni A, Merritt WM, Mangala LS, Kim SW, Shahzad MM, Tsang YT, Armaiz-Pena GN, Lu C, Kamat AA, Han LY, Spannuth WA, Nick AM, Landen CN Jr, Wong KK, Gray MJ, Coleman RL, Bodurka DC, Brinkley WR, Sood AK (2008) Targeting aurora kinase with MK-0457 inhibits ovarian cancer growth. Clin Cancer Res 14(17):5437–5446. doi:10.1158/1078-0432.CCR-07-4922 PubMedPubMedCentralCrossRef

Lin ZZ, Hsu HC, Hsu CH, Yeh PY, Huang CY, Huang YF, Chen TJ, Kuo SH, Hsu C, Hu FC, Jeng YM, Chung Y, Cheng AL (2009) The Aurora kinase inhibitor VE-465 has anticancer effects in pre-clinical studies of human hepatocellular carcinoma. J Hepatol 50(3):518–527. doi:10.1016/j.jhep.2008.10.022 PubMedCrossRef

Löwenberg B, Muus P, Ossenkoppele G, Rousselot P, Cahn JY, Ifrah N, Martinelli G, Amadori S, Berman E, Sonneveld P, Jongen-Lavrencic M, Rigaudeau S, Stockman P, Goudie A, Faderl S, Jabbour E, Kantarjian H (2011) Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia. Blood 118(23):6030–6036. doi:10.1182/blood-2011-07-366930 PubMedPubMedCentralCrossRef

Ma Y, Weimer J, Fredrik R, Adam-Klages S, Sebens S, Caliebe A, Hilpert F, Eckmann-Scholz C, Arnold N, Schem C (2013) Aurora kinase inhibitor AZD1152 has an additional effect of platinum on a sequential application at the human ovarian cancer cell line SKOV3. Arch Gynecol Obstet 288(1):173–182. doi:10.1007/s00404-013-2719-x PubMedCrossRef

Macarulla T, Cervantes A, Elez E, Rodríguez-Braun E, Baselga J, Roselló S, Sala G, Blasco I, Danaee H, Lee Y, Ecsedy J, Shinde V, Chakravarty A, Bowman D, Liu H, Eton O, Fingert H, Tabernero J (2010) Phase I study of the selective Aurora A kinase inhibitor MLN8054 in patients with advanced solid tumors: safety, pharmacokinetics, and pharmacodynamics. Mol Cancer Ther 9(10):2844–2852. doi:10.1158/1535-7163 PubMedCrossRef

Macůrek L, Lindqvist A, Lim D, Lampson MA, Klompmaker R, Freire R, Clouin C, Taylor SS, Yaffe MB, Medema RH (2008) Polo-like kinase-1 is activated by aurora A to promote checkpoint recovery. Nature 455(7209):119–123. doi:10.1038/nature07185 PubMedCrossRef

Manfredi MG, Ecsedy JA, Meetze KA, Balani SK, Burenkova O, Chen W, Galvin KM, Hoar KM, Huck JJ, LeRoy PJ, Ray ET, Sells TB, Stringer B, Stroud SG, Vos TJ, Weatherhead GS, Wysong DR, Zhang M, Bolen JB, Claiborne CF (2007) Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase. Proc Natl Acad Sci USA 104(10):4106–4111PubMedPubMedCentralCrossRef

Manfredi MG, Ecsedy JA, Chakravarty A, Silverman L, Zhang M, Hoar KM, Stroud SG, Chen W, Shinde V, Huck JJ, Wysong DR, Janowick DA, Hyer ML, Leroy PJ, Gershman RE, Silva MD, Germanos MS, Bolen JB, Claiborne CF, Sells TB (2011) Characterization of Alisertib (MLN8237), an investigational small-molecule inhibitor of aurora A kinase using novel in vivo pharmacodynamic assays. Clin Cancer Res 17(24):7614–7624. doi:10.1158/1078-0432.CCR-11-1536 PubMedCrossRef

Maris JM, Morton CL, Gorlick R, Kolb EA, Lock R, Carol H, Keir ST, Reynolds CP, Kang MH, Wu J, Smith MA, Houghton PJ (2010) Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP). Pediatr Blood Cancer 55(1):26–34. doi:10.1002/pbc.22430 PubMedPubMedCentral

Marumoto T, Honda S, Hara T, Nitta M, Hirota T, Kohmura E, Saya H (2003) Aurora-A kinase maintains the fidelity of early and late mitotic events in HeLa cells. J Biol Chem 278(51):51786–51795PubMedCrossRef

Milde-Langosch K, Bamberger AM, Rieck G, Grund D, Hemminger G, Müller V, Löning T (2005) Expression and prognostic relevance of activated extracellular-regulated kinases (ERK1/2) in breast cancer. Br J Cancer 92(12):2206–2215. doi:10.1038/sj.bjc.6602655 PubMedPubMedCentralCrossRef

Molli PR, Li DQ, Bagheri-Yarmand R, Pakala SB, Katayama H, Sen S, Iyer J, Chernoff J, Tsai MY, Nair SS, Kumar R (2010) Arpc1b, a centrosomal protein, is both an activator and substrate of Aurora A. J Cell Biol 190(1):101–114. doi:10.1083/jcb.200908050 PubMedPubMedCentralCrossRef

Moore AS, Faisal A, Gonzalez de Castro D, Bavetsias V, Sun C, Atrash B, Valenti M, de Haven BA, Avery S, Mair D, Mirabella F, Swansbury J, Pearson AD, Workman P, Blagg J, Raynaud FI, Eccles SA, Linardopoulos S (2012) Selective FLT3 inhibition of FLT3-ITD + acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns. Leukemia 26(7):1462–1470. doi:10.1038/leu.2012.52 PubMedPubMedCentralCrossRef

Moretti L, Niermann K, Schleicher S, Giacalone NJ, Varki V, Kim KW, Kopsombut P, Jung DK, Lu B (2011) MLN8054, a small molecule inhibitor of aurora kinase a, sensitizes androgen-resistant prostate cancer to radiation. Int J Radiat Oncol Biol Phys 80(4):1189–1197. doi:10.1016/j.ijrobp.2011.01.060 PubMedCrossRef

Mori D, Yamada M, Mimori-Kiyosue Y, Shirai Y, Suzuki A, Ohno S, Saya H, Wynshaw-Boris A, Hirotsune S (2009) An essential role of the aPKC-Aurora A-NDEL1 pathway in neurite elongation by modulation of microtubule dynamics. Nat Cell Biol 11(9):1057–1068. doi:10.1038/ncb1919 PubMedCrossRef

Mori N, Ishikawa C, Senba M, Kimura M, Okano Y (2011) Effects of AZD1152, a selective Aurora B kinase inhibitor, on Burkitt’s and Hodgkin’s lymphomas. Biochem Pharmacol 81(9):1106–1115. doi:10.1016/j.bcp.2011.02.010 PubMedCrossRef

Mortlock AA, Foote KM, Heron NM, Jung FH, Pasquet G, Lohmann JJ, Warin N, Renaud F, De Savi C, Roberts NJ, Johnson T, Dousson CB, Hill GB, Perkins D, Hatter G, Wilkinson RW, Wedge SR, Heaton SP, Odedra R, Keen NJ, Crafter C, Brown E, Thompson K, Brightwell S, Khatri L, Brady MC, Kearney S, McKillop D, Rhead S, Parry T, Green S (2007) Discovery, synthesis, and in vivo activity of a new class of pyrazoloquinazolines as selective inhibitors of aurora B kinase. J Med Chem 50(9):2213–2224PubMedCrossRef

Mossé YP, Lipsitz E, Fox E, Teachey DT, Maris JM, Weigel B, Adamson PC, Ingle MA, Ahern CH, Blaney SM (2012) Pediatric phase I trial and pharmacokinetic study of MLN8237, an investigational oral selective small-molecule inhibitor of Aurora kinase A: a Children’s Oncology Group Phase I Consortium study. Clin Cancer Res 18(21):6058–6064. doi:10.1158/1078-0432.CCR-11-3251 PubMedPubMedCentralCrossRef

Moy C, Oleykowski CA, Plant R, Greshock J, Jing J, Bachman K, Hardwicke MA, Wooster R, Degenhardt Y (2011) High chromosome number in hematological cancer cell lines is a negative predictor of response to the inhibition of Aurora B and C by GSK1070916. J Transl Med 9:110. doi:10.1186/1479-5876-9-110 PubMedPubMedCentralCrossRef

Muscal JA, Scorsone KA, Zhang L, Ecsedy JA, Berg SL (2013) Additive effects of vorinostat and MLN8237 in pediatric leukemia, medulloblastoma, and neuroblastoma cell lines. Invest New Drugs 31(1):39–45. doi:10.1007/s10637-012-9831-9 PubMedCrossRef

Negri JM, McMillin DW, Delmore J, Mitsiades N, Hayden P, Klippel S, Hideshima T, Chauhan D, Munshi NC, Buser CA, Pollard J, Richardson PG, Anderson KC, Mitsiades CS (2009) In vitro anti-myeloma activity of the Aurora kinase inhibitor VE-465. Br J Haematol 147(5):672–676. doi:10.1111/j.1365-2141.2009.07891.x PubMedPubMedCentralCrossRef

Niermann KJ, Moretti L, Giacalone NJ, Sun Y, Schleicher SM, Kopsombut P, Mitchell LR, Kim KW, Lu B (2011) Enhanced radiosensitivity of androgen-resistant prostate cancer: AZD1152-mediated Aurora kinase B inhibition. Radiat Res 175(4):444–451. doi:10.1667/RR2317.1 PubMedPubMedCentralCrossRef

Niu NK, Wang ZL, Pan ST, Ding HQ, Au GH, He ZX, Zhou ZW, Xiao G, Yang YX, Zhang X, Yang T, Chen XW, Qiu JX, Zhou SF (2015) Pro-apoptotic and pro-autophagic effects of the Aurora kinase A inhibitor alisertib (MLN8237) on human osteosarcoma U-2 OS and MG-63 cells through the activation of mitochondria-mediated pathway and inhibition of p38 MAPK/PI3 K/Akt/mTOR signaling pathway. Drug Des Devel Ther 9:1555–1584. doi:10.2147/DDDT.S74197 PubMedPubMedCentral

Oke A, Pearce D, Wilkinson RW, Crafter C, Odedra R, Cavenagh J, Fitzgibbon J, Lister AT, Joel S, Bonnet D (2009) AZD1152 rapidly and negatively affects the growth and survival of human acute myeloid leukemia cells in vitro and in vivo. Cancer Res 69(10):4150–4158. doi:10.1158/0008-5472 PubMedPubMedCentralCrossRef

Oslob JD, Romanowski MJ, Allen DA, Baskaran S, Bui M, Elling RA, Flanagan WM, Fung AD, Hanan EJ, Harris S, Heumann SA, Hoch U, Jacobs JW, Lam J, Lawrence CE, McDowell RS, Nannini MA, Shen W, Silverman JA, Sopko MM, Tangonan BT, Teague YJ, Yu CH, Zhong M, Zimmerman KM, O’Brien T, Lew W (2008) Discovery of a potent and selective aurora kinase inhibitor. Bioorg Med Chem Lett 18(17):4880–4884. doi:10.1016/j.bmcl.2008.07.073 PubMedCrossRef

Paller CJ, Wissing MD, Mendonca J, Sharma A, Kim E, Kim HS, Kortenhorst MS, Gerber S, Rosen M, Shaikh F, Zahurak ML, Rudek MA, Hammers H, Rudin CM, Carducci MA, Kachhap SK (2014) Combining the pan-aurora kinase inhibitor AMG 900 with histone deacetylase inhibitors enhances antitumor activity in prostate cancer. Cancer Med 3(5):1322–1335. doi:10.1002/cam4.289 PubMedPubMedCentralCrossRef

Payton M, Bush TL, Chung G, Ziegler B, Eden P, McElroy P, Ross S, Cee VJ, Deak HL, Hodous BL, Nguyen HN, Olivieri PR, Romero K, Schenkel LB, Bak A, Stanton M, Dussault I, Patel VF, Geuns-Meyer S, Radinsky R, Kendall RL (2010) Preclinical evaluation of AMG 900, a novel potent and highly selective pan-aurora kinase inhibitor with activity in taxane-resistant tumor cell lines. Cancer Res 70(23):9846–9854. doi:10.1158/0008-5472.CAN-10-3001 PubMedCrossRef

Petsalaki E, Akoumianaki T, Black EJ, Gillespie DA, Zachos G (2011) Phosphorylation at serine 331 is required for Aurora B activation. J Cell Biol 195(3):449–466. doi:10.1083/jcb.201104023 PubMedPubMedCentralCrossRef

Qi L, Zhang Y (2015) Alisertib (MLN8237), a selective Aurora-A kinase inhibitor, induces apoptosis in human tongue squamous cell carcinoma cell both in vitro and in vivo. Tumour Biol 36(3):1797–1802. doi:10.1007/s13277-014-2782-3 PubMedCrossRef

Qi W, Cooke LS, Liu X, Rimsza L, Roe DJ, Manziolli A, Persky DO, Miller TP, Mahadevan D (2011) Aurora inhibitor MLN8237 in combination with docetaxel enhances apoptosis and anti-tumor activity in mantle cell lymphoma. Biochem Pharmacol 81(7):881–890. doi:10.1016/j.bcp.2011.01.017 PubMedPubMedCentralCrossRef

Ratushny V, Pathak HB, Beeharry N, Tikhmyanova N, Xiao F, Li T, Litwin S, Connolly DC, Yen TJ, Weiner LM, Godwin AK, Golemis EA (2012) Dual inhibition of SRC and Aurora kinases induces postmitotic attachment defects and cell death. Oncogene 31(10):1217–1227. doi:10.1038/onc.2011.314 PubMedCrossRef

Reboutier D, Troadec MB, Cremet JY, Fukasawa K, Prigent C (2012) Nucleophosmin/B23 activates Aurora A at the centrosome through phosphorylation of serine 89. J Cell Biol 197(1):19–26. doi:10.1083/jcb.201107134 PubMedPubMedCentralCrossRef

Ritchey L, Ottman R, Roumanos M, Chakrabarti R (2012) A functional cooperativity between Aurora A kinase and LIM kinase1: implication in the mitotic process. Cell Cycle 11(2):296–309. doi:10.4161/cc.11.2.18734 PubMedPubMedCentralCrossRef

Sasai K, Katayama H, Stenoien DL, Fujii S, Honda R, Kimura M, Okano Y, Tatsuka M, Suzuki F, Nigg EA, Earnshaw WC, Brinkley WR, Sen S (2004) Aurora-C kinase is a novel chromosomal passenger protein that can complement Aurora-B kinase function in mitotic cells. Cell Motil Cytoskeleton 59(4):249–263PubMedCrossRef

Saskova A, Solc P, Baran V, Kubelka M, Schultz RM, Motlik J (2008) Aurora kinase A controls meiosis I progression in mouse oocytes. Cell Cycle 7(15):2368–2376PubMedPubMedCentralCrossRef

Schöffski P, Jones SF, Dumez H, Infante JR, Van Mieghem E, Fowst C, Gerletti P, Xu H, Jakubczak JL, English PA, Pierce KJ, Burris HA (2011) Phase I, open-label, multicentre, dose-escalation, pharmacokinetic and pharmacodynamic trial of the oral aurora kinase inhibitor PF-03814735 in advanced solid tumours. Eur J Cancer 47(15):2256–2264. doi:10.1016/j.ejca.2011.07.008 PubMedCrossRef

Schwartz GK, Carvajal RD, Midgley R, Rodig SJ, Stockman PK, Ataman O, Wilson D, Das S, Shapiro GI (2013) Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B kinase, in patients with advanced solid tumors. Invest New Drugs 31(2):370–380. doi:10.1007/s10637-012-9825-7 PubMedCrossRef

Sehdev V, Peng D, Soutto M, Washington MK, Revetta F, Ecsedy J, Zaika A, Rau TT, Schneider-Stock R, Belkhiri A, El-Rifai W (2012) The aurora kinase A inhibitor MLN8237 enhances cisplatin-induced cell death in esophageal adenocarcinoma cells. Mol Cancer Ther 11(3):763–774. doi:10.1158/1535-7163 PubMedPubMedCentralCrossRef

Seymour JF, Kim DW, Rubin E, Haregewoin A, Clark J, Watson P, Hughes T, Dufva I, Jimenez JL, Mahon FX, Rousselot P, Cortes J, Martinelli G, Papayannidis C, Nagler A, Giles FJ (2014) A phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia. Blood Cancer J 4:e238. doi:10.1038/bcj.2014.6 PubMedPubMedCentralCrossRef

Shimomura T, Hasako S, Nakatsuru Y, Mita T, Ichikawa K, Kodera T, Sakai T, Nambu T, Miyamoto M, Takahashi I, Miki S, Kawanishi N, Ohkubo M, Kotani H, Iwasawa Y (2010) MK-5108, a highly selective Aurora-A kinase inhibitor, shows antitumor activity alone and in combination with docetaxel. Mol Cancer Ther 9(1):157–166. doi:10.1158/1535-7163 PubMedCrossRef

Shuda K, Schindler K, Ma J, Schultz RM, Donovan PJ (2009) Aurora kinase B modulates chromosome alignment in mouse oocytes. Mol Reprod Dev 76(11):1094–1105. doi:10.1002/mrd.21075 PubMedPubMedCentralCrossRef

Slattery SD, Moore RV, Brinkley BR, Hall RM (2008) Aurora-C and Aurora-B share phosphorylation and regulation of CENP-A and Borealin during mitosis. Cell Cycle 7(6):787–795PubMedCrossRef

Slattery SD, Mancini MA, Brinkley BR, Hall RM (2009) Aurora-C kinase supports mitotic progression in the absence of Aurora-B. Cell Cycle 8(18):2984–2994PubMedCrossRef

Soncini C, Carpinelli P, Gianellini L, Fancelli D, Vianello P, Rusconi L, Storici P, Zugnoni P, Pesenti E, Croci V, Ceruti R, Giorgini ML, Cappella P, Ballinari D, Sola F, Varasi M, Bravo R, Moll J (2006) PHA-680632, a novel Aurora kinase inhibitor with potent antitumoral activity. Clin Cancer Res 12(13):4080–4089PubMedCrossRef

Spengler D (2007) The protein kinase Aurora C phosphorylates TRF2. Cell Cycle 6(20):2579–2580PubMedCrossRef

Svensson S, Jirström K, Rydén L, Roos G, Emdin S, Ostrowski MC, Landberg G (2005) ERK phosphorylation is linked to VEGFR2 expression and Ets-2 phosphorylation in breast cancer and is associated with tamoxifen treatment resistance and small tumors with good prognosis. Oncogene 24(27):4370–4379. doi:10.1038/sj.onc.1208626 PubMedCrossRef

Tao Y, Zhang P, Frascogna V, Lecluse Y, Auperin A, Bourhis J, Deutsch E (2007) Enhancement of radiation response by inhibition of Aurora-A kinase using siRNA or a selective Aurora kinase inhibitor PHA680632 in p53-deficient cancer cells. Br J Cancer 97(12):1664–1672PubMedPubMedCentralCrossRef

Tao Y, Zhang P, Girdler F, Frascogna V, Castedo M, Bourhis J, Kroemer G, Deutsch E (2008) Enhancement of radiation response in p53-deficient cancer cells by the Aurora-B kinase inhibitor AZD1152. Oncogene 27(23):3244–3255PubMedCrossRef

Traynor AM, Hewitt M, Liu G, Flaherty KT, Clark J, Freedman SJ, Scott BB, Leighton AM, Watson PA, Zhao B, O’Dwyer PJ, Wilding G (2011) Phase I dose escalation study of MK-0457, a novel Aurora kinase inhibitor, in adult patients with advanced solid tumors. Cancer Chemother Pharmacol 67(2):305–314. doi:10.1007/s00280-010-1318-9 PubMedCrossRef

Tsuboi K, Yokozawa T, Sakura T, Watanabe T, Fujisawa S, Yamauchi T, Uike N, Ando K, Kihara R, Tobinai K, Asou H, Hotta T, Miyawaki S (2011) A Phase I study to assess the safety, pharmacokinetics and efficacy of barasertib (AZD1152), an Aurora B kinase inhibitor, in Japanese patients with advanced acute myeloid leukemia. Leuk Res 35(10):1384–1389. doi:10.1016/j.leukres.2011.04.008 PubMedCrossRef

Van Brocklyn JR, Wojton J, Meisen WH, Kellough DA, Ecsedy JA, Kaur B, Lehman NL (2014) Aurora-A inhibition offers a novel therapy effective against intracranial glioblastoma. Cancer Res 74(19):5364–5370. doi:10.1158/0008-5472 PubMedPubMedCentralCrossRef

VanderPorten EC, Taverna P, Hogan JN, Ballinger MD, Flanagan WM, Fucini RV (2009) The Aurora kinase inhibitor SNS-314 shows broad therapeutic potential with chemotherapeutics and synergy with microtubule-targeted agents in a colon carcinoma model. Mol Cancer Ther 8(4):930–939. doi:10.1158/1535-7163 PubMedCrossRef

Venkatakrishnan K, Zhou X, Ecsedy J, Mould DR, Liu H, Danaee H, Fingert H, Kleinfield R, Milton A (2014) Dose selection for the investigational anticancer agent alisertib (MLN8237): pharmacokinetics, pharmacodynamics, and exposure-safety relationships. J Clin Pharmacol. doi:10.1002/jcph.410 PubMed

Walsby E, Walsh V, Pepper C, Burnett A, Mills K (2008) Effects of the aurora kinase inhibitors AZD1152-HQPA and ZM447439 on growth arrest and polyploidy in acute myeloid leukemia cell lines and primary blasts. Haematologica 93(5):662–669. doi:10.3324/haematol.12148 PubMedCrossRef

Walter AO, Seghezzi W, Korver W, Sheung J, Lees E (2000) The mitotic serine/threonine kinase Aurora2/AIK is regulated by phosphorylation and degradation. Oncogene 19(42):4906–4916PubMedCrossRef

Wilkinson RW, Odedra R, Heaton SP, Wedge SR, Keen NJ, Crafter C, Foster JR, Brady MC, Bigley A, Brown E, Byth KF, Barrass NC, Mundt KE, Foote KM, Heron NM, Jung FH, Mortlock AA, Boyle FT, Green S (2007) AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis. Clin Cancer Res 13(12):3682–3688PubMedCrossRef

Willder JM, Heng SJ, McCall P, Adams CE, Tannahill C, Fyffe G, Seywright M, Horgan PG, Leung HY, Underwood MA, Edwards J (2013) Androgen receptor phosphorylation at serine 515 by Cdk1 predicts biochemical relapse in prostate cancer patients. Br J Cancer 108(1):139–148. doi:10.1038/bjc.2012.480 PubMed

Wu X, Liu W, Cao Q, Chen C, Chen Z, Xu Z, Li W, Liu F, Yao X (2014) Inhibition of Aurora B by CCT137690 sensitizes colorectal cells to radiotherapy. J Exp Clin Cancer Res. doi:10.1186/1756-9966-33-13

Xia W, Chen JS, Zhou X, Sun PR, Lee DF, Liao Y, Zhou BP, Hung MC (2004) Phosphorylation/cytoplasmic localization of p21Cip1/WAF1 is associated with HER2/neu overexpression and provides a novel combination predictor for poor prognosis in breast cancer patients. Clin Cancer Res 10(11):3815–3824. doi:10.1158/1078-0432.CCR-03-0527 PubMedCrossRef

Yan X, Cao L, Li Q, Wu Y, Zhang H, Saiyin H, Liu X, Zhang X, Shi Q, Yu L (2005) Aurora C is directly associated with Survivin and required for cytokinesis. Genes Cells 10(6):617–626PubMedCrossRef

Yang J, Ikezoe T, Nishioka C, Tasaka T, Taniguchi A, Kuwayama Y, Komatsu N, Bandobashi K, Togitani K, Koeffler HP, Taguchi H, Yokoyama A (2007) AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo. Blood 110(6):2034–2040PubMedCrossRef

Yang KT, Li SK, Chang CC, Tang CJ, Lin YN, Lee SC, Tang TK (2010) Aurora-C kinase deficiency causes cytokinesis failure in meiosis I and production of large polyploid oocytes in mice. Mol Biol Cell 21(14):2371–2383. doi:10.1091/mbc.E10-02-0170 PubMedPubMedCentralCrossRef

Yao R, Zheng J, Zheng W, Gong Y, Liu W, Xing R (2014) VX680 suppresses the growth of HepG2 cells and enhances the chemosensitivity to cisplatin. Oncol Lett 7(1):121–124PubMed

Yasui Y, Urano T, Kawajiri A, Nagata K, Tatsuka M, Saya H, Furukawa K, Takahashi T, Izawa I, Inagaki M (2004) Autophosphorylation of a newly identified site of Aurora-B is indispensable for cytokinesis. J Biol Chem 279(13):12997–13003PubMedCrossRef

Yoshida K, Nagai T, Ohmine K, Uesawa M, Sripayap P, Ishida Y, Ozawa K (2011) Vincristine potentiates the anti-proliferative effect of an aurora kinase inhibitor, VE-465, in myeloid leukemia cells. Biochem Pharmacol 82(12):1884–1890. doi:10.1016/j.bcp.2011.09.015 PubMedCrossRef

Young MA, Shah NP, Chao LH, Seeliger M, Milanov ZV, Biggs WH 3rd, Treiber DK, Patel HK, Zarrinkar PP, Lockhart DJ, Sawyers CL, Kuriyan J (2006) Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680. Cancer Res 66(2):1007–1014PubMedCrossRef

Zeitlin SG, Shelby RD, Sullivan KF (2001) CENP-A is phosphorylated by Aurora B kinase and plays an unexpected role in completion of cytokinesis. J Cell Biol 55(7):1147–1157CrossRef

Zekri A, Ghaffari SH, Ghanizadeh-Vesali S, Yaghmaie M, Salmaninejad A, Alimoghaddam K, Modarressi MH, Ghavamzadeh A (2015) AZD1152-HQPA induces growth arrest and apoptosis in androgen-dependent prostate cancer cell line (LNCaP) via producing aneugenic micronuclei and polyploidy. Tumour Biol 36(2):623–632. doi:10.1007/s13277-014-2664-8 PubMedCrossRef

Zhang L, Zhang S (2011) ZM447439, the Aurora kinase B inhibitor, suppresses the growth of cervical cancer SiHa cells and enhances the chemosensitivity to cisplatin. J Obstet Gynaecol Res 37(6):591–600. doi:10.1111/j.1447-0756.2010.01414.x PubMedCrossRef

Zhao ZS, Lim JP, Ng YW, Lim L, Manser E (2005) The GIT-associated kinase PAK targets to the centrosome and regulates Aurora-A. Mol Cell 20(2):237–249PubMedCrossRef

Zhou N, Singh K, Mir MC, Parker Y, Lindner D, Dreicer R, Ecsedy JA, Zhang Z, Teh BT, Almasan A, Hansel DE (2013) The investigational Aurora kinase A inhibitor MLN8237 induces defects in cell viability and cell-cycle progression in malignant bladder cancer cells in vitro and in vivo. Clin Cancer Res 19(7):1717–1728. doi:10.1158/1078-0432.CCR-12-2383 PubMedPubMedCentralCrossRef

Zoubir M, Tursz T, Ménard C, Zitvogel L, Chaput N (2010) Imatinib mesylate (Gleevec): targeted therapy against cancer with immune properties. Endocr Metab Immune Disord Drug Targets 10(1):1–7PubMedCrossRef

Springer Medizin

The Aurora kinase inhibitors in cancer research and therapy

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2016

Prognostic and predictive value of the novel classification of lung adenocarcinoma in patients with stage IB

Disseminated and circulating tumor cells in bone marrow and blood of breast cancer patients: properties, enrichment, and potential targets

Evaluation of assays for drug efficacy in a three-dimensional model of the lung

High-risk clinicopathological features and their predictive significance in Korean patients with stage II colon cancer